| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
EDUCATION EXHIBIT |
1 From the Department of Radiology, Allegheny General Hospital, 320 E North Ave, Pittsburgh, PA 15212 (M.B.F.) and the Departments of Radiology (T.M.B., D.W.T., C.C.M.), Otolaryngology (C.H.S., J.J.J., E.N.M.), Psychiatry (C.C.M.), and Neurology (C.C.M.), University of Pittsburgh, Pa. Presented as an education exhibit at the 2001 RSNA Annual Meeting. Received June 28, 2004; revision requested July 22 and received March 11, 2005; accepted March 14. T.M.B. is a consultant for Petnet Pharmaceuticals; D.W.T. is a consultant for CPS Innovations; all remaining authors have no financial relationships to disclose. Address correspondence to M.B.F. (e-mail: mfukui{at}wpahs.org).
Positron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) is effective for monitoring head and neck cancer. However, lack of anatomic landmarks, variable physiologic FDG uptake, and asymmetric FDG distribution in the neck can confound image interpretation. This is particularly true in the treated neck, where distortion of normal tissue planes makes detection of early disease recurrence difficult with conventional computed tomography (CT) and magnetic resonance imaging. Combined PET-CT helps prevent the misinterpretation of FDG PET findings in patients with head and neck cancer. Superior localization of FDG uptake with this technique can improve diagnostic accuracy and help avoid interpretative pitfalls. In the future, development of tumor-specific ligands will enhance the usefulness of PET-CT in the detection of initial tumors and tumor recurrence, in the evaluation of tumors with low FDG avidity, and in treatment targeting. Furthermore, improved scanner resolution will help address the limitations of PET-CT with respect to small lesions and may make this modality more valuable in initial tumor staging.
© RSNA, 2005
Related Article
RadioGraphics 2005 25: 897-912.
This article has been cited by other articles:
|
|
 |
|
  Y ARIJI, N FUWA, T KODAIRA, H TACHIBANA, T NAKAMURA, Y SATOH, and E ARIJI False-positive positron emission tomography appearance with 18F-fluorodeoxyglucose after definitive radiotherapy for cancer of the mobile tongue Br. J. Radiol., January 1, 2009; 82(973): e3 - e7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nahmias, C. Lemmens, D. Faul, E. Carlson, M. Long, T. Blodgett, J. Nuyts, and D. Townsend Does Reducing CT Artifacts from Dental Implants Influence the PET Interpretation in PET/CT Studies of Oral Cancer and Head and Neck Cancer? J. Nucl. Med., July 1, 2008; 49(7): 1047 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y-H CHEN, J J-M JIAN, K-Y CHAN, S Y TSAI, S H CHENG, K-C L YEN, and J C-H CHENG Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings Br. J. Radiol., June 1, 2008; 81(966): 490 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Schuetze, L. H. Baker, R. S. Benjamin, and R. Canetta Selection of Response Criteria for Clinical Trials of Sarcoma Treatment Oncologist, April 1, 2008; 13(suppl_2): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Roh, C. H. Ryu, S.-H. Choi, J. S. Kim, J. H. Lee, K.-J. Cho, S. Y. Nam, and S. Y. Kim Clinical Utility of 18F-FDG PET for Patients with Salivary Gland Malignancies J. Nucl. Med., February 1, 2007; 48(2): 240 - 246. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOGRAPHICS | RADIOLOGY | RSNA JOURNALS ONLINE |
